Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements.

Sugimoto, Danny H; Dex, Terry; Stager, William; Aroda, Vanita R

Sugimoto, Danny H; Dex, Terry; Stager, William; Aroda, Vanita R.

Affiliation

Sugimoto DH; Cedar Crosse Research Center, Chicago, Illinois.
Dex T; Sanofi US Inc., Bridgewater, New Jersey.
Stager W; Sanofi US Inc., Bridgewater, New Jersey.
Aroda VR; Brigham and Women's Hospital, Boston, Massachusetts.

Diabetes Obes Metab ; 20(11): 2680-2684, 2018 11.

Article in En | MEDLINE | ID: mdl-29923361

Subject(s)

Diabetes Mellitus, Type 2/drug therapy; Insulin Glargine/administration & dosage; Peptides/administration & dosage; Aged; Aged, 80 and over; Blood Glucose/drug effects; Blood Glucose/metabolism; Datasets as Topic; Diabetes Mellitus, Type 2/metabolism; Diabetes Mellitus, Type 2/pathology; Drug Combinations; Female; Glycated Hemoglobin/drug effects; Glycated Hemoglobin/metabolism; Humans; Insulin Glargine/adverse effects; Male; Middle Aged; Peptides/adverse effects; Retrospective Studies; Risk Factors; Treatment Outcome

Key words

GLP-1; antidiabetic drug; glycaemic control; hypoglycaemia; type 2 diabetes

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peptides / Diabetes Mellitus, Type 2 / Insulin Glargine Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2018 Type: Article

Fulltext

XML

PubMed Links

Search on Google